Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trialRussell E. Ware, Robert J. Adams, Barry R. Davis et al.|The Lancet|2015Cited by 518
Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFRMahboob Rahman, Richard A. Preston, Lawrence J. Fine et al.|Clinical Journal of the American Society of Nephrology|2012Cited by 94
Characteristics and Long-Term Follow-Up of Participants with Peripheral Arterial Disease During ALLHATLinda B. Piller, Barry R. Davis, Lara M. Simpson et al.|Journal of General Internal Medicine|2014Cited by 49
TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell AnemiaRussell E. Ware, Robert J. Adams, Barry R. Davis et al.|Blood|2015Cited by 17
Characteristics and Lipid Distribution of a Large, High‐Risk, Hypertensive Population: The Lipid‐Lowering Component of the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Vasilios Papademetriou, Gabriel B. Habib, Linda B. Piller et al.|Journal of Clinical Hypertension|2003Cited by 15